What question did this study set out to answer?

To review the genetic and environmental risk factors underlying drug-induced acquired long QT syndrome and assess the feasibility of preventative pharmacogenetic testing.

April 1, 2005Pharmacogenomics

Pharmacogenomics and Acquired Long QT Syndrome

View Full Paper

Ask AI

Bookmark

Population

Individuals at risk of acquired long QT syndrome (LQTS) due to drug exposure

Design

Review

Authors

JAJeroen AerssensHasselt University APAimée PaulussenMaastricht University Medical Centre

Discussion

Member takes

Implication

May inform acquired LQTS risk stratification; hypothesis-generating and requires prospective validation before clinical adoption.

Key Points

To review the genetic and environmental risk factors underlying drug-induced acquired long QT syndrome and assess the feasibility of preventative pharmacogenetic testing.
Reviewed literature on clinical reports of drug-induced QT prolongation, torsades de pointes, and drug withdrawals across cardiac and non-cardiac therapeutics.
Evaluated molecular mechanisms linking silent mutations in ion channel genes and drug-metabolizing enzyme polymorphisms to arrhythmia susceptibility.
Acquired long QT syndrome is frequently associated with silent mutations and functional polymorphisms in cardiac ion channel genes identical to those in congenital forms.
Genetic variations in drug-metabolizing enzymes elevate arrhythmia risk by altering systemic drug clearance, particularly in the setting of polypharmacy.
Clinical vulnerability is exacerbated by non-genetic triggers, including female sex, hypokalemia, and pre-existing cardiac disorders.

Structured PICO

Population

Individuals at risk of acquired long QT syndrome (LQTS) due to drug exposure

Intervention

Pharmacogenetic testing and evaluation of genetic risk factors (e.g., ion channel mutations, drug-metabolizing enzyme polymorphisms)

Outcome

Risk of acquired long QT syndrome and torsades de pointes

Genetic polymorphisms in ion channels and drug-metabolizing enzymes are important risk factors for drug-induced acquired long QT syndrome, suggesting a future role for pharmacogenetic screening.

Cite This Study

Aerssens et al. (2005) studied this question.

synapsesocial.com/papers/6a7bfca74fcef545fadf9609 https://doi.org/10.1517/14622416.6.3.259

View Full Paper

Ask AI

Bookmark

Pharmacogenomics and Acquired Long QT Syndrome

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Pharmacogenomics and Acquired Long QT Syndrome

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider